Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90

Chemistry & Biology
Maria VilenchikGabriela Chiosis

Abstract

Agents that inhibit Hsp90 function hold significant promise in cancer therapy. Here we present PU24FCl, a representative of the first class of designed Hsp90 inhibitors. By specifically and potently inhibiting tumor Hsp90, PU24FCl exhibits wide-ranging anti-cancer activities that occur at similar doses in all tested tumor types. Normal cells are 10- to 50-fold more resistant to these effects. Its Hsp90 inhibition results in multiple anti-tumor-specific effects, such as degradation of Hsp90-client proteins involved in cell growth, survival, and specific transformation, inhibition of cancer cell growth, delay of cell cycle progression, induction of morphological and functional changes, and apoptosis. In concordance with its higher affinity for tumor Hsp90, in vivo PU24FCl accumulates in tumors while being rapidly cleared from normal tissue. Concentrations achieved in vivo in tumors lead to single-agent anti-tumor activity at non-toxic doses.

References

Jan 1, 1995·Cancer Chemotherapy and Pharmacology·J G SupkoL Malspeis
Nov 17, 1998·The Journal of Cell Biology·W M ObermannF U Hartl
Jan 19, 2000·Trends in Biochemical Sciences·R Dutta, M Inouye
Mar 29, 2000·The Journal of Biological Chemistry·C Spampinato, P Modrich
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Jun 28, 2001·Oncogene·J Mendelsohn, J Baselga
Jan 5, 2002·Expert Opinion on Biological Therapy·Alison Maloney, Paul Workman
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelMichael Press
Mar 21, 2002·Expert Opinion on Therapeutic Targets·Jeremy R Graff
Apr 3, 2002·Trends in Molecular Medicine·Len Neckers
May 31, 2002·Journal of Medicinal Chemistry·Daniel F VeberKenneth D Kopple
Feb 5, 2003·Onkologie·R A HilgerD Strumberg
Oct 8, 2003·Current Cancer Drug Targets·Alison MaloneyPaul Workman
Oct 8, 2003·Current Cancer Drug Targets·Gabriela ChiosisNeal Rosen
Nov 1, 2003·Bioorganic & Medicinal Chemistry Letters·Laura Llauger-BufiGabriela Chiosis

❮ Previous
Next ❯

Citations

May 31, 2007·Journal of Biosciences·Len Neckers
Aug 1, 2013·Pathology Oncology Research : POR·J M Patki, S S Pawar
Dec 6, 2012·Archives of Pharmacal Research·Hyun Kyung Choi, Kyeong Lee
Nov 17, 2005·Oncogene·Keyong Du, Philip N Tsichlis
May 31, 2008·Proceedings of the National Academy of Sciences of the United States of America·Giorgio ColomboGennady Verkhivker
Aug 17, 2012·Proceedings of the National Academy of Sciences of the United States of America·Carmel T ChanSanjiv S Gambhir
Dec 8, 2010·Assay and Drug Development Technologies·James H AhnGabriela Chiosis
Mar 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David B SolitHoward I Scher
Jan 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sarat ChandarlapatyDavid B Solit
Apr 9, 2010·PloS One·Rongmin ZhaoWalid A Houry
May 23, 2007·Proceedings of the National Academy of Sciences of the United States of America·Wenjie LuoGabriela Chiosis
Jan 31, 2006·Expert Opinion on Therapeutic Targets·Gabriela Chiosis
Jul 12, 2005·Expert Opinion on Investigational Drugs·Jennifer S Isaacs
Jan 1, 2008·Expert Opinion on Drug Discovery·Gabriela ChiosisWeilin Sun
Mar 11, 2005·Expert Opinion on Emerging Drugs·Len Neckers, Katharine Neckers
Mar 29, 2014·Expert Opinion on Investigational Drugs·Komal JhaveriGabriela Chiosis
Jun 15, 2007·FEBS Letters·Marissa V Powers, Paul Workman
Jun 2, 2012·Experimental Cell Research·Hajare MjahedCarmen Garrido
May 23, 2012·Journal of Molecular Graphics & Modelling·Sharad VermaAbha Mishra
Jan 31, 2009·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Yanyan LiDuxin Sun
Aug 8, 2006·Current Opinion in Drug Discovery & Development·Martin J DrysdaleJoseph Schoepfer
Sep 20, 2005·British Journal of Pharmacology·Csaba SõtiPéter Ferdinandy
May 15, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marco BreinigMichael André Kern
Feb 13, 2008·Journal of Cellular and Molecular Medicine·D LanneauC Garrido
Jan 30, 2013·The FEBS Journal·Jared J Barrott, Timothy A J Haystead
Jan 22, 2005·Current Opinion in Genetics & Development·Laurence H Pearl
Oct 12, 2004·Drug Discovery Today·Gabriela ChiosisDavid Solit
Mar 17, 2006·The International Journal of Biochemistry & Cell Biology·Antal OroszAndras Perczel
Nov 9, 2011·Biochimica Et Biophysica Acta·Komal JhaveriGabriela Chiosis
Sep 30, 2014·Trends in Pharmacological Sciences·Tony TaldoneGabriela Chiosis
Jun 1, 2014·Biochemical and Biophysical Research Communications·Shaoxiang WangYifei Wang
Jun 23, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yong LiShu-Fan Yin
Oct 11, 2005·Bioorganic & Medicinal Chemistry Letters·Paul A BroughPaul Workman
Jan 30, 2007·Journal of Biomolecular Screening·Jeffrey SzwayaChang-Rung Chen
Nov 8, 2006·Nature Clinical Practice. Urology·Jean-Baptiste LattoufLeonard Neckers
Jul 3, 2007·Nature Chemical Biology·Anna RodinaGabriela Chiosis
Nov 10, 2018·The Journal of Biological Chemistry·Tai WangGabriela Chiosis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis